Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-ascending dose study of LY3537031 in healthy participants
jRCT2031200242Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing LY3537031 with Placebo (2 arms). Primary endpoint: Number of participants with one or more serious adverse events. Started Dec 2020; status: completed.
02
Drugs
LY3537031
Beyond the preview
Go deeper on jRCT2031200242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200242.